<DOC>
	<DOCNO>NCT01194622</DOCNO>
	<brief_summary>The primary objective ass effect azelastine hydrochloride ( AZE ) relative bioavailability ( AUC0-∞ ) fluticasone propionate ( FLU ) administer fix AZE-FLU combination product ( TEST ) compare similar formulation without contain AZE ( i.e . FLU alone MP29-02 vehicle ; REF ) . The secondary objective compare relative bioavailability ( AUC0-∞ ) FLU administer either fix AZE-FLU combination product ( TEST ) market FLU product , Fluticasone Propionate Nasal Spray , Roxane Laboratories ( COMP ) ; To compare effect AZE pharmacokinetic parameter FLU ( AUC0 tlast , CL/f , Cmax , tmax , t½ ) ; To assess adverse event .</brief_summary>
	<brief_title>Single Dose Pharmacokinetics Intranasal Fluticasone Delivered Fixed Combination With Azelastine ( MP29 02 ) Comparison Two Different Fluticasone Nasal Sprays</brief_title>
	<detailed_description>This study enrol healthy subject . It consider study result discriminative healthy subject rhinitis patient interference vary rhinitis symptom respective difference status nasal mucosa regard 3 study period . The time schedule serum sampling ( pre-dose 8 , 15 , 30 , 45 min , 1 , 1¼ , 1½ , 2 , 2½ , 3 , 4 , 6 , 8 , 12 , 24 h p.a. , time refer end second spray second nostril administration ) derive previous bioavailability study assume mean tmax 1 h p.a . [ P5 ] mean t1/2 3 h [ L9 ] . Sampling time expect cover AUC0-tlast 80 % total AUC fluticasone propionate ( bioanalytical detection method LLOQ 0.5 pg/mL ) .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Azelastine</mesh_term>
	<criteria>1 . Male female healthy subject Ethnic origin , age 18 45 year . 2 . Body mass index ( BMI ) 18.5 30.0 kg/m2 . 3 . Use adequate double contraception female childbearing potential ( i.e . woman child bear potential use highly effective method birth control define result low failure rate ( i.e . &lt; 1 % per year ) use consistently correctly implant , injectables , combine oral contraceptive , hormonal IUDs ) surgically sterile ( documented complete hysterectomy bitubal ligation ; partial hysterectomy sufficient vasectomised partner ) . It must ensure male partner use condom intercourse ( surgically sterilize ) . 4 . Use adequate double contraception male , sexually active man surgically sterilize , must consent us condom intercourse ensures female partner practice adequate contraception ( highly effective method birth control define result low failure rate ( i.e . &lt; 1 % per year ) use consistently correctly implant , injectables , combine oral contraceptive , hormonal IUDs ) surgically sterile ( documented complete hysterectomy bitubal ligation ; partial hysterectomy sufficient ) . 5 . Written informed consent . 6 . Able demonstrate correct nasal spray application technique screen . 1 . History allergic reaction sensitivity fluticasone propionate , azelastine hydrochloride one excipients ( e.g . benzalkoniumchloride , phenylethyl alcohol , microcrystalline cellulose ) . 2 . Any evidence clinically relevant acute chronic cardiovascular , pulmonary , hepatic , renal , gastrointestinal , haematological , endocrine , metabolic , mental , neurological , disease screening . 3 . Positive ßHCG pregnancy test , establish pregnancy , breastfeed plan pregnancy study . Lack suitability study : 4 . History haemophilia coagulation disease . 5 . Significant history orthostatic hypotension , faint blackout . 6 . Existence surgical medical condition , might significantly alter absorption , distribution , metabolism , excretion study drug . 7 . Chronic clinically relevant acute infection ( e.g . respiratory tract include sinusitis rhinitis ) , acute rhinorrhoea febrile disease week randomisation . 8 . Clinical chemical , haematological laboratory parameter clinically relevant outside reference range ( e.g . elevate liver enzyme , renal laboratory parameter , coagulation abnormality abnormalities platelet count , prothrombin time , activate partial thromboplastin time ) . 9 . Positive result HIV , HCV HBsAg test . 10 . ECG abnormalities clinical relevance , particular abnormal prolongation QT/QTc PQinterval ( i.e . QTc accord Fridericia ≥ 450 m , PQ ≥ 220 m ) . 11 . Resting heart rate awake subject 45 BPM 90 BPM , systolic blood pressure 100 mmHg 145 mmHg , diastolic blood pressure 95 mmHg . 12 . Regular therapy corticosteroid ( e.g . fluticasone propionate ) antihistamine ( e.g . azelastine hydrochloride ) . 13 . Any concurrent medication medication within 2 week precede start study ( single intake/use drug may accept , judge investigator clinical relevance influence study outcome ) . 14 . Exposure cytochrome P450 3A4 inhibit induce drug ( e.g . ritonavir , ketoconazole , itraconazole , erythromycin , rifampicin , St. John 's wort ( Hypericum perforatum ) etc . ) diet ( charcoal grill meat , brussels sprout , broccoli ) beverage ( e.g . grapefruit juice ) within 14 day prior study enrolment , anticipated consumption product period time throughout study . 15 . History nasal surgery know clinically relevant abnormality , rhinitis medicamentosa , polyposis , septum deviation clinical symptom , nasal structural abnormality . 16 . Known perennial airway allergy vasomotor rhinitis . Known seasonal airway allergy clinically relevant acute within last six week prior start study might become acute study period . 17 . History malignancy within past five year . 18 . Blood donation within last 2 month prior start study . 19 . Present history drug alcohol abuse within last three year . Regular daily consumption half litre usual beer 0.25 L wine per day equivalent quantity approximately 30 g alcohol another form . 20 . Current smoker smoking last year . 21 . Exposure investigational medicinal product within last 3 month . 22 . Subject report regular xanthine consumption &gt; 5 cup coffee black tea per day ( equivalent xanthine consumption ≥ 500 mg xanthine per day use product ) . 23 . Subject vegetarian report strict dietary habit would preclude subject 's acceptance standardize meal . Administrative reason : 24 . Lack ability willingness give inform consent . 25 . Lack willingness personal study relate data collect , archive transmit accord protocol . 26 . Lack willingness inability cooperate adequately . 27 . Anticipated nonavailability study visits/procedures . 28 . Vulnerable subject ( person keep detention ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>